Clinical trialPhase 1Unknown
AMT-151 in Patients With Selected Advanced Solid Tumours
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
- Outcome
- Outcome unknown
- Phase
- Phase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- 25 January 2023
- Listed end
- 30 October 2024
- Enrollment
- 30 participants
- Sites
- 9
- Primary outcomes
- Recommended Phase 2 Dose (RP2D); Maximum Tolerated Dose (MTD); Incidence of Adverse Events
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 19 October 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.